Integra LifeSciences Holdings Corp. 10-Q Summary
Business Context and Reporting Period
Company: Integra LifeSciences Holdings Corporation (IART)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Integra is a global medical technology company operating in two reportable segments: Specialty Surgery (Neurosurgery, Surgical Instruments, ENT Solutions) and Tissue Reconstruction (Wound Reconstruction, Private Label). The company manufactures and sells medical technologies for neurosurgery, neurocritical care, and tissue repair.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue, Net | $418,761 | $810,679 | $798,258 |
| Gross Margin | $219,744 (52.5%) | $436,726 (53.9%) | $403,764 (50.6%) |
| Operating Income (Loss) | $19,285 | $30,755 | $(528,171) |
| Net Income (Loss) | $4,482 | $(134) | $(509,366) |
| Diluted EPS | $0.06 | $0.00 | $(6.65) |
| Cash & Equivalents | $214,415 | $214,415 | $217,914 |
| Short-Term Investments | $59,669 | $59,669 | $28,693 |
| Total Debt (Carrying Value) | $1,872,299 | $1,872,299 | $1,856,106 |
| Operating Cash Flow | N/A | $32,605 | $(2,338) |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $4.5 million for the quarter and a negligible loss of $0.1 million for the six months ended June 30, 2026. This is a significant improvement compared to the prior year, which included a massive $511.4 million goodwill impairment charge in Q2 2025.
- Revenue Growth: Total revenue increased 0.8% year-over-year for the quarter ($418.8M vs $415.6M) and 1.6% for the six months ($810.7M vs $798.3M). Specialty Surgery revenue grew 2% in the quarter, while Tissue Reconstruction declined 2%.
- Gross Margin Expansion: Gross margin percentage improved to 52.5% (Q2) and 53.9% (YTD) from 50.4% and 50.6% in the prior year, driven by reduced costs associated with the Braintree facility remediation and improved manufacturing performance.
- Operating Expenses: Total operating expenses decreased significantly year-over-year, primarily due to the absence of the prior year's goodwill impairment charge. SG&A and R&D expenses also declined due to reduced integration and EU MDR compliance costs.
- Debt Structure: The company repaid its 0.5% Convertible Senior Notes ($575M) in August 2025 using revolver borrowings. Interest expense increased due to higher rates on the revolving credit facility compared to the retired notes.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Event (Flood Damage): On July 17, 2026, the company's Cincinnati, Ohio manufacturing facility sustained flood damage. The financial impact is currently being assessed, and the company does not expect a material adverse effect on operations at this time, though insurance recoveries are pending.
- Tariff Refunds: Following a U.S. Supreme Court ruling invalidating certain IEEPA tariffs, the company recognized a $19.0 million receivable for tariff refunds. $0.5 million in cash refunds were received in the first half of 2026.
- Regulatory Matters: The company continues to address FDA warning letters related to quality system issues at facilities in Massachusetts, New Jersey, and the Boston facility. The Braintree facility became operational in June 2026 to support the relaunch of SurgiMend in Q4 2026.
- Restructuring: The company is executing a restructuring initiative approved in Q4 2025, with expected aggregate costs of $12.3 million. $3.8 million was incurred in the first half of 2026.
- Legal Proceedings: The company successfully defended an arbitration regarding the ACell acquisition earnout. A securities class action (Pembroke Litigation) remains pending, with the company filing motions to dismiss.
- Debt Covenants: The company is in compliance with all covenants. The Consolidated Total Leverage Ratio was 4.10x as of June 30, 2026, well below the 5.00x covenant requirement.
Investor Verification Checklist
- Cincinnati Flood Impact: Verify the final assessment of asset damage, inventory loss, and insurance recovery amounts following the July 17, 2026 flood event.
- Tariff Refund Realization: Monitor the status of the $17.6 million in submitted IEEPA tariff refund claims and the timing of cash receipts.
- FDA Compliance: Track the resolution of FDA warning letters and the successful commercial relaunch of SurgiMend from the Braintree facility in Q4 2026.
- Debt Servicing: Review the impact of higher interest rates on the revolving credit facility on future interest expense and cash flow.
- Restructuring Costs: Confirm the total cost and timeline for the completion of the $12.3 million restructuring initiative.